Literature DB >> 21998210

Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.

Ebba K Lindqvist1, Lynn R Goldin, Ola Landgren, Cecilie Blimark, Ulf-Henrik Mellqvist, Ingemar Turesson, Anders Wahlin, Magnus Björkholm, Sigurdur Y Kristinsson.   

Abstract

The associations between immune-related conditions and multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) have previously been investigated with inconsistent results. In a large population-based study, we identified 19 112 patients with MM, 5403 patients with MGUS, 96 617 matched control subjects, and 262 931 first-degree relatives. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for the association of MM and MGUS with immune-related conditions by use of logistic regression. A personal history of all infections combined was associated with a significantly increased risk of MM (OR = 1.2; 95% CI, 1.1-1.3), and a personal history of all conditions in the categories infections (OR = 1.6; 95% CI, 1.5-1.7), inflammatory conditions (OR = 1.4; 95% CI, 1.2-1.5), and autoimmune diseases (OR = 2.1; 95% CI, 1.9-2.4) was associated with a significantly increased risk of MGUS. Several specific immune-related conditions elevated the risk of MM and/or MGUS. A family history of autoimmune disease was associated with a significantly increased risk of MGUS (OR = 1.1; 95% CI, 1.00-1.2), but not MM. Our findings suggest that immune-related conditions and/or their treatment are of importance in the etiology of MGUS and possibly MM. The association of both personal and family history of autoimmune disease with MGUS indicates the potential for shared susceptibility for these conditions.

Entities:  

Mesh:

Year:  2011        PMID: 21998210      PMCID: PMC3236117          DOI: 10.1182/blood-2011-04-347559

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis.

Authors:  H Gregersen; G Pedersen; N Svendsen; A M Thulstrup; H T Sørensen; H C Schønheyder
Journal:  APMIS       Date:  2001-11       Impact factor: 3.205

2.  [Reliability of the hospital registry. The diagnostic data are better than their reputation].

Authors:  A C Nilsson; C L Spetz; K Carsjö; R Nightingale; B Smedby
Journal:  Lakartidningen       Date:  1994-02-16

3.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

Authors:  H A Isomäki; T Hakulinen; U Joutsenlahti
Journal:  J Chronic Dis       Date:  1978

4.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

5.  Rheumatoid arthritis and cancer risk.

Authors:  L Mellemkjaer; M S Linet; G Gridley; M Frisch; H Møller; J H Olsen
Journal:  Eur J Cancer       Date:  1996-09       Impact factor: 9.162

6.  Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.

Authors:  M Neovius; A Sundström; Jf Simard; B Wettermark; T Cars; N Feltelius; J Askling; L Klareskog
Journal:  Scand J Rheumatol       Date:  2010-10-18       Impact factor: 3.641

7.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

8.  Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.

Authors:  I C MacLennan; C Chapman; J Dunn; K Kelly
Journal:  Lancet       Date:  1992-01-25       Impact factor: 79.321

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  26 in total

Review 1.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

2.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23

3.  Autoimmune autonomic ganglionopathy associated with monoclonal gammopathy of undetermined significance: a case report.

Authors:  Tatsuya Ueno; Takashi Nakamura; Akira Arai; Chieko Suzuki; Masahiko Tomiyama
Journal:  Neurol Sci       Date:  2019-01-26       Impact factor: 3.307

4.  Familial associations of monoclonal gammopathy of unknown significance with autoimmune diseases.

Authors:  K Hemminki; A Försti; K Sundquist; J Sundquist; X Li
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

5.  Risk factors for monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Maira A Castaneda-Avila; Christine M Ulbricht; Mara Meyer Epstein
Journal:  Ann Hematol       Date:  2021-01-08       Impact factor: 3.673

6.  Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case-control study from Sweden.

Authors:  Sigurdur Y Kristinsson; Ying Gao; Magnus Björkholm; Sigrun Helga Lund; Jan Sjöberg; Neil Caporaso; Lynn R Goldin; Ola Landgren
Journal:  Int J Hematol       Date:  2015-03-11       Impact factor: 2.490

7.  Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Authors:  Marianna Thordardottir; Ebba K Lindqvist; Sigrun H Lund; Rene Costello; Debra Burton; Neha Korde; Sham Mailankody; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-01

8.  Search for multiple myeloma risk factors using Mendelian randomization.

Authors:  Molly Went; Alex J Cornish; Philip J Law; Ben Kinnersley; Mark van Duin; Niels Weinhold; Asta Försti; Markus Hansson; Pieter Sonneveld; Hartmut Goldschmidt; Gareth J Morgan; Kari Hemminki; Björn Nilsson; Martin Kaiser; Richard S Houlston
Journal:  Blood Adv       Date:  2020-05-26

Review 9.  Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions.

Authors:  Elisabet E Manasanch; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-07

10.  Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Ola Landgren; Lesley A Anderson
Journal:  Int J Cancer       Date:  2013-10-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.